Tirzepatide for Sleep Apnea: The SURMOUNT-OSA Evidence
Released · Last reviewed
SURMOUNT-OSA showed tirzepatide significantly reduced the severity of obstructive sleep apnea in adults with obesity, leading to FDA approval of Zepbound for moderate-to-severe OSA in 2024 — the first drug approved for the condition.
- SURMOUNT-OSA tested tirzepatide in adults with obesity and moderate-to-severe OSA.
- Tirzepatide markedly reduced apnea-hypopnea index (AHI) vs placebo.
- Zepbound became the first drug FDA-approved for OSA (2024).
- The approval is for the brand product, not compounded tirzepatide.
What SURMOUNT-OSA tested
SURMOUNT-OSA was a pair of randomized trials testing tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea (OSA), a condition in which the airway repeatedly collapses during sleep. One trial studied patients using CPAP therapy and one studied patients not using it.
The primary measure was the apnea-hypopnea index (AHI), the number of breathing interruptions per hour of sleep — the standard metric of OSA severity.
The trials asked whether tirzepatide, by producing substantial weight loss, could meaningfully reduce OSA severity.
The results
Tirzepatide produced a large reduction in AHI compared with placebo in both trials, substantially decreasing the number of breathing interruptions per hour. Many participants improved enough to change their OSA severity category, and some met criteria for disease resolution.
The improvements accompanied significant weight loss, consistent with the understanding that excess weight is a major driver of OSA in many patients.
These results led the FDA to approve Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity in late 2024, the first medication ever approved for the condition.
| Element | Detail |
|---|---|
| Population | Adults with obesity + moderate-severe OSA |
| Measure | Apnea-hypopnea index (AHI) |
| Result | Large AHI reduction vs placebo |
| Outcome | Zepbound FDA-approved for OSA (2024) |
What it means for patients
For patients with obesity and OSA, this evidence offers a medication option that treats both conditions at once. It does not necessarily replace CPAP for everyone, but it gives clinicians a new tool, especially for patients who struggle with CPAP adherence.
The approval is specific: moderate-to-severe OSA in adults with obesity. It is not a general sleep aid, and its benefit is tied to the weight loss and metabolic effects of tirzepatide.
Patients should view it as part of a broader OSA management plan directed by their clinician, not a standalone cure.
Compounded tirzepatide and OSA
The SURMOUNT-OSA evidence and the FDA approval apply to the brand product, Zepbound. Compounded tirzepatide was not studied for OSA and is not approved for it.
As with other GLP-1 evidence, the trial results attach to the specific approved product, not to every preparation containing the molecule. It is not valid to assume a compounded product delivers the same OSA benefit.
A patient specifically seeking OSA treatment has a strong reason to discuss the approved product with a clinician.
| Applies to | Does not apply to |
|---|---|
| Brand Zepbound for OSA | Compounded tirzepatide for OSA |
| Adults with obesity + OSA | General sleep complaints |
The bottom line
SURMOUNT-OSA showed tirzepatide significantly reduces obstructive sleep apnea severity in adults with obesity, leading to Zepbound's 2024 approval as the first drug for OSA.
The benefit is tied to weight loss and applies to the approved brand product, not compounded tirzepatide. It is a new option within OSA management, not a universal replacement for CPAP.
This is educational information; OSA treatment decisions belong with your clinician.
Frequently asked questions
What did SURMOUNT-OSA show?
Tirzepatide significantly reduced obstructive sleep apnea severity (AHI) in adults with obesity, leading to Zepbound's FDA approval for OSA in 2024.
Is tirzepatide approved for sleep apnea?
Zepbound (brand tirzepatide) is FDA-approved for moderate-to-severe OSA in adults with obesity. Compounded tirzepatide is not.
Does it replace CPAP?
Not necessarily. It is a new option, especially for patients who struggle with CPAP, but OSA management should be directed by a clinician.
Does compounded tirzepatide help OSA?
It was not studied for OSA and is not approved for it. The evidence applies to the brand product.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- NEJM — STEP, SELECT, SURMOUNT, SURPASS, SUSTAIN, PIONEER, FLOW, SURMOUNT-OSA trials.
- ClinicalTrials.gov and prescribing information.
- Evidence policy: evidence policy.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $86 to $299 a month across the 24 programmes we priced on October 15, 2026, with a median of $144. The spread is $213 a month, or $2,556 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $126 and Eden at $129; lower stickers come with a sale, a prepaid term or a membership. Half the programmes sit below $144 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Four programmes printed a tirzepatide microdose price on October 15, 2026, from $116 (Telos RX, "as low as") to $199 (Shed). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
How tirzepatide is kept current
On October 15, 2026, compounded tirzepatide ran $86 to $299 a month across the 24 programmes we priced. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
Standard-dose tirzepatide spans $86 to $299 a month across the 24 programmes we priced on October 15, 2026, a spread of $213.
The molecule is chemically identical across every programme in the range. The $230 a month between the lowest and highest all-in semaglutide prices we read on October 15, 2026 ($49 and $279) is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why is microdosed tirzepatide cheaper?
Because it is less medicine. On October 15, 2026, four programs printed a tirzepatide microdose price, from $116 (Telos RX, "as low as") to $199 (Shed); NexLife's microdose plan was $189 month-to-month or $147 a month on 12 months; since November 8, 2026 it is $129 or $115, the same as the standard plan. A microdose sits below every dose studied in the pivotal trials.
What does compounded tirzepatide cost per month in October 2026?
As of October 15, 2026, the 24 compounded tirzepatide programs we could price on their own pages charge between $86 and $299 a month at their lowest all-in rate, with a median of $144, counting any required membership and the cheapest plan term each program prints. The $86 figure is Collective's $69 monthly price plus its $199 annual membership spread over twelve months. Standing month-to-month rates with no membership start at $126 (Mondae) and $129 (Eden); as of November 6, 2026, NexLife is $129 month-to-month and $115 on a 12-month plan. Compounded tirzepatide is not FDA-approved.
What does compounded tirzepatide normally cost?
$86 to $299 a month at the lowest all-in rate across the 24 programs we priced on October 15, 2026, with a median of $144. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.